Search results
Kosei ITO, Professor (Full) | Cited by 7,275 | of Nagasaki University, Nagasaki | Read 97 publications | Contact Kosei ITO
Matsubara T, Iga T, Sugiura Y, Kusumoto D, Sanosaka T, Tai-Nagara I, Takeda N, Fong GH, Kosei Ito, Ema M, Okano H, Kohyama J, Suematsu M, Kubota M. Journal of Experimental Medicine 219 (4) e20211789 2022年4月4日 査読有り. Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma.
Jul 4, 2023 · Kosei Ito. Oncogene 42 , 2485–2494 ( 2023) Cite this article. 542 Accesses. 1 Citations. 2 Altmetric. Metrics. Abstract. Osteosarcoma (OS) is characterized by TP53 mutations in...
Research theme for competitive and other funds (14)：. 2022 - 2025 組織マクロファージの動的恒常性維持機能を標的軸としたデザイナー細胞医薬の開発. 2021 - 2024 Integrated understanding of molecular mechanisms of osteosarcoma development focusing on Myc super-enhancer.
The mutation R122C in RUNX3 promotes gastric carcinogenesis by unclear mechanisms. We investigated how Runx3-deficiency contributes to distinct changes in the gastric epithelium that precede neoplasia. Methods: Runx3-deficient (Runx3 (-/-)) and wild-type BALB/c adult mice were subjected to histological analyses.
- Kosei Ito, Linda Shyue Huey Chuang, Tomoko Ito, Ti Ling Chang, Hiroshi Fukamachi, Manuel Salto–Telle...
- 2011
Nov 22, 2021 · Kosei Ito Oncogene (2023) EZH2 regulates a SETDB1/ΔNp63α axis via RUNX3 to drive a cancer stem cell phenotype in squamous cell carcinoma
Feb 2, 2020 · Chang T.L., Ito K., Ko T.K., Liu Q., Salto-Tellez M., Yeoh K.G., Fukamachi H., Ito Y. Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology.
